Akoya BioSciences
AKYA
AKYA was delisted on the 7th of July, 2025.
63 hedge funds and large institutions have $109M invested in Akoya BioSciences in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 16 closing their positions.
169% more call options, than puts
Call options by funds: $277K | Put options by funds: $103K
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
2.22% less ownership
Funds ownership: 37.06% → 34.84% (-2.2%)
14% less funds holding
Funds holding: 73 → 63 (-10)
19% less capital invested
Capital invested by funds: $135M → $109M (-$25.5M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$2.61M |
| 2 |
ACM
Altium Capital Management
New York
|
+$1.78M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.13M |
| 4 |
Millennium Management
New York
|
+$998K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$982K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HEC
Hudson Executive Capital
New York
|
-$5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2.75M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.73M |
| 4 |
CEI
Clark Estates Inc
New York
|
-$1.63M |
| 5 |
RI
RTW Investments
New York
|
-$1.62M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWS
76
Glassman Wealth Services
Vienna,
Virginia
| – | -$134 | -14 | Closed |
|
77
Simplex Trading
Chicago,
Illinois
| – | -$42 | -4 | Closed |
|
|
CS
78
Credit Suisse
Zurich,
Switzerland
| – | -$10 | -1 | Closed |
|
AKYA Hedge Fund Activity: Q1 2023 in Review
63 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q1 2023, worth a combined $109M — down 19% from $135M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AKYA and 6 opened new positions — a net loss of 10 holders — while 21 trimmed existing stakes and 25 added.
The largest buyer was Blue Water Life Science Advisors, adding an estimated $2.61M. The largest seller was Hudson Executive Capital, cutting an estimated $5M.
- 63 institutional investors held Akoya BioSciences (AKYA) as of Q1 2023, down from 73 in Q4 2022.
- Funds reported $109M of Akoya BioSciences stock for Q1 2023, down 19% quarter-over-quarter.
- 6 funds opened new Akoya BioSciences positions in Q1 2023 and 16 closed out, a net change of -10 holders.
- The largest Akoya BioSciences buyer in Q1 2023 was Blue Water Life Science Advisors, an estimated $2.61M added.
- The largest Akoya BioSciences seller in Q1 2023 was Hudson Executive Capital, an estimated $5M sold.
Based on aggregated 13F filings for Q1 2023.